Decision support to help germline genetic testing for men with prostate cancer
Official title: Efforts to Enhance Germline Genetic Testing at Lyndon B. Johnson Hospital
Run by M.D. Anderson Cancer Center · NCT07377006 · Data updated 2026-11-12
A tool is being tested to help men with prostate cancer decide about germline genetic testing and see if it increases testing completion.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 108 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | May 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT07377006 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with diagnosed prostate cancer receiving care at LBJ Hospital who were recommended for germline genetic testing and can consent in English or Spanish.
✕Probably not a fit
Patients who are not offered or recommended germline testing, or those unable to participate due to cognitive or significant psychological impairment, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to identify factors that influence whether patients complete recommended germline genetic testing and to develop a culturally tailored decision support tool. The study includes qualitative interviews, cognitive testing of the tool draft, and a pilot test of the tool in a public safety net hospital in Harris County, Texas. The pilot evaluates feasibility, impact on testing completion, and incorporates genetic counseling and standard biospecimen collection as part of the workflow. The intervention targets English- and Spanish-speaking patients and leverages electronic health records to support at-risk individuals and their families. Outcomes focus on testing uptake and the practicality of implementing the tool in routine care.
Why it matters
Potential benefit: If successful, the tool could increase appropriate germline testing and improve access to targeted therapies and clinical trials for patients and families.
How similar studies have gone: Prior efforts using decision support and tailored education in genetics have shown promise in improving testing uptake in other settings, but this specific, culturally tailored, point-of-care tool in a safety-net population is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital * Were recommended for germline genetic testing by their oncology provider * Can provide informed consent * Can communicate in English or Spanish Exclusion Criteria: * Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Debanjan Pain — M.D. Anderson Cancer Center
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding NK Cell Function in Prostate Cancer Across Races
This study tests whether natural killer (NK) cells behave differently in prostate cancer patients of diverse racial backgrounds by analyzing blood and tissue samples.
-
MRI or CT planning to guide high-dose-rate prostate brachytherapy
This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.
-
Targeted Early Detection for Men at High Genetic Risk for Prostate Cancer
This study tests urinary biomarkers and PSA to see if they can improve early detection for men with a strong family or genetic risk for prostate cancer.
-
Urine and MRI approach to find aggressive prostate cancer early
This study tests whether a urine test called MPS2, paired with MRI, can better detect aggressive prostate cancer in men 50–75 at risk, possibly reducing unnecessary biopsies.
-
GET FIT Together: a socially enhanced exercise program for older men with prostate cancer
This program tests whether adding structured social support to supervised online exercise reduces cancer-related loneliness and improves mental and physical health in men 65 and older who have had prostate cancer.
-
Improved MRI methods to distinguish benign from cancerous pelvic findings
This test tries new deep-learning image-processing methods on MRI scans to get clearer images faster for adults scanned for prostate screening or suspected endometriosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.